id,gene_symbol,protein_name,tier,evidence_priority,has_structure,surface_class,pdb_count_total,alphafold_mean_pLDDT,has_cryoEM,has_activation_state_pdb_pair,activation_state_pdb_active,activation_state_pdb_inactive,has_known_aptamer,aptamer_count_pubmed,aptamer_pmids,in_cev_map,opentargets_top_disease_name,opentargets_top_disease_score
P36021,SLC16A2,Monocarboxylate transporter 8,Tier 1.5,0.956,1,A_surface,7,79.56,1,0,,,0,0,,1,Allan-Herndon-Dudley syndrome,0.8533069932022032
P51795,CLCN5,H(+)/Cl(-) exchange transporter 5,Tier 1.5,0.955,1,A_surface,2,80.62,0,0,,,0,0,,1,Dent disease type 1,0.850724240157394
Q14524,SCN5A,Sodium channel protein type 5 subunit alpha,Tier 1.5,0.953,1,A_surface,16,67.25,1,0,,,0,0,,1,long QT syndrome 3,0.8448298602976083
Q969N2,PIGT,GPI-anchor transamidase component PIGT,Tier 1.5,0.953,1,A_surface,3,87.25,1,0,,,0,0,,1,multiple congenital anomalies-hypotonia-seizures syndrome 3,0.8439030764005646
P13637,ATP1A3,Sodium/potassium-transporting ATPase subunit alpha-3,Tier 1.5,0.953,1,A_surface,5,88.81,1,0,,,0,0,,1,alternating hemiplegia of childhood 2,0.842328126568451
Q99250,SCN2A,Sodium channel protein type 2 subunit alpha,Tier 1.5,0.952,1,A_surface,5,68.81,1,0,,,0,0,,1,"developmental and epileptic encephalopathy, 11",0.8388748085806758
P25189,MPZ,Myelin protein P0,Tier 1.5,0.951,1,A_surface,2,81.69,0,0,,,0,0,,1,Charcot-Marie-Tooth disease type 1B,0.8377022197539885
Q9HAB3,SLC52A2,"Solute carrier family 52, riboflavin transporter, member 2",Tier 1.5,0.95,1,A_surface,1,84.12,1,0,,,0,0,,1,riboflavin transporter deficiency,0.8333271825486935
Q9Y653,ADGRG1,Adhesion G-protein coupled receptor G1,Tier 1.5,0.95,1,A_surface,1,77.88,1,0,,,0,0,,1,bilateral frontoparietal polymicrogyria,0.8322298896713178
P13473,LAMP2,Lysosome-associated membrane glycoprotein 2,Tier 1.5,0.948,1,A_surface,2,83.19,0,0,,,0,0,,1,Glycogen Storage Disease Type 2b,0.8273010649608126
P14770,GP9,Platelet glycoprotein IX,Tier 1.5,0.947,1,A_surface,2,84.69,1,0,,,0,0,,1,Bernard-Soulier syndrome,0.8233582238860002
P51798,CLCN7,H(+)/Cl(-) exchange transporter 7,Tier 1.5,0.942,1,A_surface,9,80.94,1,0,,,0,0,,1,Autosomal recessive malignant osteopetrosis,0.8065499095904218
Q96JI7,SPG11,Spatacsin,Tier 1.5,0.937,1,A_surface,3,66.75,1,0,,,0,0,,1,Autosomal recessive spastic paraplegia type 11,0.7886006646085494
Q8TD43,TRPM4,Transient receptor potential cation channel subfamily M member 4,Tier 1.5,0.936,1,A_surface,25,77.44,1,0,,,0,0,,1,Familial progressive cardiac conduction defect,0.7868180621357534
P05023,ATP1A1,Sodium/potassium-transporting ATPase subunit alpha-1,Tier 1.5,0.936,1,A_surface,10,88.69,1,0,,,0,0,,1,"Charcot-Marie-tooth disease, axonal, type 2DD",0.7868851290226483
O94856,NFASC,Neurofascin,Tier 1.5,0.933,1,A_surface,2,76.31,0,0,,,0,0,,1,neurodevelopmental disorder with central and peripheral motor dysfunction,0.7782432580663833
Q15746,MYLK,"Myosin light chain kinase, smooth muscle",Tier 1.5,0.93,1,A_surface,7,65.88,0,0,,,0,0,,1,"aortic aneurysm, familial thoracic 7",0.7659842793171938
Q02094,RHAG,Ammonium transporter Rh type A,Tier 1.5,0.929,1,A_surface,8,95.62,1,0,,,0,0,,1,Rh deficiency syndrome,0.764209214915708
P00846,MT-ATP6,ATP synthase F(0) complex subunit a,Tier 1.5,0.928,1,A_surface,10,88.94,1,0,,,0,0,,1,NARP syndrome,0.760749518172638
Q02413,DSG1,Desmoglein-1,Tier 1.5,0.92,1,A_surface,1,62.06,0,0,,,0,0,,1,severe dermatitis-multiple allergies-metabolic wasting syndrome,0.7335328506238418
O15554,KCNN4,Intermediate conductance calcium-activated potassium channel protein 4,Tier 1.5,0.914,1,A_surface,17,84.19,1,0,,,0,0,,1,dehydrated hereditary stomatocytosis,0.7145864899974032
O75110,ATP9A,Probable phospholipid-transporting ATPase IIA,Tier 1.5,0.914,1,A_surface,4,84.19,1,0,,,0,0,,1,neurodevelopmental disorder with poor growth and behavioral abnormalities,0.7120328673255018
Q9NR82,KCNQ5,Potassium voltage-gated channel subfamily KQT member 5,Tier 1.5,0.913,1,A_surface,5,56.41,1,0,,,0,0,,1,"intellectual disability, autosomal dominant 46",0.7086662845211597
P51797,CLCN6,H(+)/Cl(-) exchange transporter 6,Tier 1.5,0.897,1,A_surface,3,77.81,1,0,,,0,0,,1,"neurodegeneration, childhood-onset, with hypotonia, respiratory insufficiency, and brain imaging abnormalities",0.6554030932062199
P21731,TBXA2R,Thromboxane A2 receptor,Tier 1.5,0.892,1,A_surface,6,86.25,1,0,,,0,0,,1,bleeding diathesis due to thromboxane synthesis deficiency,0.639967145559869
Q13555,CAMK2G,Calcium/calmodulin-dependent protein kinase type II subunit gamma,Tier 1.5,0.891,1,A_surface,2,78.38,0,0,,,0,0,,1,intellectual developmental disorder 59,0.6354497016986491
P54709,ATP1B3,Sodium/potassium-transporting ATPase subunit beta-3,Tier 1.5,0.88,1,A_surface,7,89.69,1,0,,,0,0,,1,congestive heart failure,0.5999952111132625
Q92956,TNFRSF14,Tumor necrosis factor receptor superfamily member 14,Tier 1.5,0.879,1,A_surface,8,79.94,0,0,,,0,0,,1,diffuse large B-cell lymphoma,0.5983171413833771
P01597,IGKV1-39,Immunoglobulin kappa variable 1-39,Tier 1.5,0.876,1,A_surface,2,90.5,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P01764,IGHV3-23,Immunoglobulin heavy variable 3-23,Tier 1.5,0.876,1,A_surface,6,91.0,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P01825,IGHV4-59,Immunoglobulin heavy variable 4-59,Tier 1.5,0.876,1,A_surface,3,91.56,1,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P23083,IGHV1-2,Immunoglobulin heavy variable 1-2,Tier 1.5,0.876,1,A_surface,1,91.75,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P01593,IGKV1D-33,Immunoglobulin kappa variable 1D-33,Tier 1.5,0.876,1,A_surface,6,90.88,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P06312,IGKV4-1,Immunoglobulin kappa variable 4-1,Tier 1.5,0.876,1,A_surface,10,90.62,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P15954,COX7C,"Cytochrome c oxidase subunit 7C, mitochondrial",Tier 1.5,0.868,1,A_surface,3,91.38,1,0,,,0,0,,1,neurodegenerative disease,0.5589133210585959
P41440,SLC19A1,Reduced folate transporter,Tier 1.5,0.866,1,A_surface,19,72.06,1,0,,,0,0,,1,Knobloch syndrome,0.5526223217595396
Q96D96,HVCN1,Voltage-gated hydrogen channel 1,Tier 1.5,0.865,1,A_surface,2,69.75,0,0,,,0,0,,1,Joubert syndrome,0.5504227269701596
Q9P1W8,SIRPG,Signal-regulatory protein gamma,Tier 1.5,0.864,1,A_surface,2,85.5,0,0,,,0,0,,1,type 1 diabetes mellitus,0.5457344827318543
O15155,BET1,BET1 homolog,Tier 1.5,0.864,1,A_surface,1,83.06,0,0,,,0,0,,1,neurodegenerative disease,0.5468418315282804
P34741,SDC2,Syndecan-2,Tier 1.5,0.863,1,A_surface,1,60.84,0,0,,,0,0,,1,COVID-19,0.5422254875204983
Q8TEM1,NUP210,Nuclear pore membrane glycoprotein 210,Tier 1.5,0.862,1,A_surface,2,79.56,1,0,,,0,0,,1,HIV infection,0.5409211817593593
O00161,SNAP23,Synaptosomal-associated protein 23,Tier 1.5,0.859,1,A_surface,2,82.12,0,0,,,0,0,,1,neurodegenerative disease,0.5288361677964304
P54756,EPHA5,Ephrin type-A receptor 5,Tier 1.5,0.858,1,A_surface,2,79.38,0,0,,,0,0,,1,neurodegenerative disease,0.5261379875719714
Q9HCM2,PLXNA4,Plexin-A4,Tier 1.5,0.856,1,A_surface,1,83.06,0,0,,,0,0,,1,neurodegenerative disease,0.518371001420808
Q9Y6M7,SLC4A7,Sodium bicarbonate cotransporter 3,Tier 1.5,0.856,1,A_surface,1,67.5,1,0,,,0,0,,1,hypertension,0.5199335074832467
P15814,IGLL1,Immunoglobulin lambda-like polypeptide 1,Tier 1.5,0.85,1,A_surface,3,75.06,0,0,,,0,0,,1,isolated agammaglobulinemia,0.4996673834185043
P18084,ITGB5,Integrin beta-5,Tier 1.5,0.846,1,A_surface,3,82.19,0,0,,,0,0,,1,migraine disorder,0.48652455084344876
Q92536,SLC7A6,Y+L amino acid transporter 2,Tier 1.5,0.846,1,A_surface,2,83.19,1,0,,,0,0,,1,Abnormality of the skeletal system,0.48544421359843914
P14616,INSRR,Insulin receptor-related protein,Tier 1.5,0.838,1,A_surface,4,78.0,1,0,,,0,0,,1,neurodegenerative disease,0.4589515676875687
A1L3X0,ELOVL7,Very long chain fatty acid elongase 7,Tier 1.5,0.828,1,A_surface,1,89.75,0,0,,,0,0,,1,substance-related disorder,0.4271436896798171